Revelation Biosciences (REVB) Stock Soars 90% After Reporting Trial Results

  • Revelations Biosciences (REVB) stock is jumping 90% after the company reported the results of a study of its hay fever treatment.
  • The drug met its primary endpoints related to safety and tolerability.
  • However, the treatment did not meet secondary endpoints related to efficacy.
REVB stock - Revelation Biosciences (REVB) Stock Soars 90% After Reporting Trial Results

Source: Hernan E. Schmidt /

Revelation Biosciences (NASDAQ:REVB) stock is up 91% today, and searches for REVB stock are trending. The drug maker reported that its treatment for hay fever, REVTx-99b, had met its primary endpoint in a Phase 1b trial. The company made the announcement on Friday after the stock market closed.

The trial’s primary endpoint was safety and tolerability, and the study did indicate that Revelation’s drug was safe and tolerable.

However, REVTx-99b did not meet secondary endpoints that were related to its efficacy as a treatment for hay fever. In other words, multiple data points suggested that REVTx-99b does not relieve the symptoms of hay fever more effectively than a placebo does.

“Revelation management plans to evaluate future development of this and other ongoing programs,” the company reported.

The Second Miss on Efficacy This Year

In March, the company announced that, in a Phase 2b trial that there were no indications that its treatment for influenza, REVTx-99a, had reduced the viral load of 30 flu patients. Moreover, “the preliminary results suggest the difference between REVTx-99a and placebo was not statistically significant,” Revelation reported at the time.

The company suggested that it was giving up on its flu treatment candidate. Specifically, CEO, James Rolke, said in a statement that:

We remain committed to the development of our other product candidates including REVTx-99b for management of allergic rhinitis and other underlying conditions; and REVDx-501, our universal at home screening test for respiratory viral infection.

However, Rolke did not state that Revelation would continue to pursue its flu treatment.

The Bottom Line on REVB Stock

“With two trial flounders in recent months, Revelation’s operations are murky,” wrote Kyle LaHucik, the associate editor of Endpoints News today.

LaHucik’s statement is both accurate and concerning. Indeed, given the lack of efficacy demonstrated so far by the company’s products, I find it hard to understand why REVB stock is climbing at all today, let alone nearly doubling in value.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Larry Ramer did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.

Article printed from InvestorPlace Media,

©2022 InvestorPlace Media, LLC